期刊
FRONTIERS IN MEDICINE
卷 8, 期 -, 页码 -出版社
FRONTIERS MEDIA SA
DOI: 10.3389/fmed.2021.697338
关键词
COVID-19; acute respiratory distress syndrome; extracorporeal membrane oxygenation; extracorporeal life support (ECLS); respiratory failure
资金
- National Key Research and Development Project of the Ministry of Science and Technology, China [2018YFC1313700]
- Gaoyuan Project of Pudong Health and Family Planning Commission [PWYgy2018-6]
- Research Foundation of Shanghai Science and Technology Commission [18140904100]
ECMO may be an effective treatment for critically ill patients with COVID-19, but careful patient selection and management by a trained team are crucial. More randomized controlled trials with larger sample sizes are needed to evaluate the actual effectiveness of ECMO in patients with COVID-19.
Covid-19, Coronavirus disease 2019; ARDS, Acute respiratory distress syndrome; ECMO, Extracorporeal Membrane Oxygenation; WHO, World Health Organization; ICUs, Intensive care units. Acute respiratory distress syndrome (ARDS) is a fatal comorbidity of critically ill patients with COVID-19, who often end up on respiratory support. However, the safety and effectiveness of Extracorporeal Membrane Oxygenation (ECMO) in the treatment of COVID-19 remains to be elucidated at present. Here, we report on nine patients who received ECMO due to severe SARS-CoV-2 infection in Wuhan, China. Our initial experiences suggest that carefully selecting patients, as well as management by a well-trained team, are critical to implementing ECMO in patients with COVID-19. More randomized controlled trials with larger sample sizes are needed to evaluate the usefulness of ECMO in patients with COVID-19.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据